

The direct effects of non-steroidal anti-inflammatory drugs (NSAIDs) on osteoarthritic knee cartilage

Submission date 20/12/2005	Recruitment status No longer recruiting	☐ Prospectively registered
Registration date 20/12/2005	Overall study status Completed	☐ Protocol
Last Edited 15/05/2009	Condition category Musculoskeletal Diseases	☐ Statistical analysis plan
		☐ Results
		☐ Individual participant data
		☐ Record updated in last year

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Dr A C A Marijnissen

Contact details

UMC Utrecht
Rheumatology & Clin. Immunology, F02.127
P.O. Box 85500
Utrecht
Netherlands
3508 GA
+31 (0)30 250 9758
a.c.a.marijnissen@umcutrecht.nl

Additional identifiers

Protocol serial number

NTR159

Study information

Scientific Title

Selective COX-2 inhibition is beneficial for matrix turnover: a clinical study

Study objectives

Selective COX-2 inhibition is beneficial for matrix turnover.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Received from the local medical ethics committee

Primary study design

Interventional

Study design

Randomised active controlled parallel group trial

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Osteoarthritis

Interventions

Celecoxib: 4 weeks, 2 times per day, 200 mg

Naproxen: 4 weeks, 3 times per day, 250 mg

Indomethacin: 4 weeks, 2 times per day, 50 mg

Intervention Type

Drug

Phase

Not Applicable

Drug/device/biological/vaccine name(s)

Celecoxib, naproxen, indomethacin

Primary outcome(s)

Difference in proteoglycan release of osteoarthritic cartilage after treatment

Key secondary outcome(s)

Proteoglycan E2 levels produced by cartilage

Completion date

01/12/2005

Eligibility

Key inclusion criteria

Patients with knee osteoarthritis according to the American College of Rheumatology (ACR) criteria, considered for total knee replacement surgery.

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Not Specified

Sex

Not Specified

Key exclusion criteria

1. Total knee replacement for other reason than osteoarthritis
2. History of gastro-intestinal bleedings or perforation
3. Increased risk for cardiovascular diseases (cardiovascular diseases in history, patients with untreated hypertension, patients with angina pectoris, and patients on oral anticoagulants)

Date of first enrolment

01/11/2004

Date of final enrolment

01/12/2005

Locations**Countries of recruitment**

Netherlands

Study participating centre

UMC Utrecht

Utrecht

Netherlands

3508 GA

Sponsor information**Organisation**

University Medical Centre Utrecht (UMCU) (Netherlands)

ROR

<https://ror.org/04pp8hn57>

Funder(s)

Funder type

Not defined

Funder Name

Not provided at time of registration

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration